Back to Search
Start Over
CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases
- Source :
- Disease markers. Section A, Cancer biomarkers, info:cnr-pdr/source/autori:Paratore, Sabrina; Banna, Giuseppe Luigi; D'Arrigo, Maria; Saita, Salvatore; Iemmolo, Rosario; Lucenti, Letizia; Bellia, Domenico; Lipari, Helga; Buscarino, Calogero; Cunsolo, Rosario; Cavallaro, Sebastiano/titolo:CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases/doi:10.3233%2FCBM-2011-0232/rivista:Disease markers. Section A, Cancer biomarkers (Print)/anno:2011/pagina_da:79/pagina_a:89/intervallo_pagine:79–89/volume:10
- Publication Year :
- 2011
- Publisher :
- IOS Press, Tokyo , Paesi Bassi, 2011.
-
Abstract
- Synchronous or metachronous brain metastases (BMs) occur in about 33% of patients affected by non-small-cell lung cancer (NSCLC). To date, no reliable biological marker is able to identify patients who will develop BMs. In the present study, using a quantitative double-labeling immunofluorescence analysis, we evaluated the expression of chemokine CXCL12 and its receptor, CXCR4, in primary NSCLC histological specimens of patients with and without BMs. The immunoreactivity of CXCL12 and CXCR4 was significantly higher in NSCLC samples of patients with BMs. We performed Receiver Operating Characteristics (ROC) analysis in order to define optimal cut-off values for CXCL12 and CXCR4 immunoreactivity that could discriminate between NSCLC patients without and with BMs. ROC curves showed a good diagnostic accuracy and adequate predictive power for both CXCL12 and CXCR4. These findings suggest a possible role for the CXCL12/CXCR4 axis in the metastatic evolution of NSCLC, and its potential use as prognostic markers and drug targets.
- Subjects :
- Male
Receptors, CXCR4
Cancer Research
Pathology
medicine.medical_specialty
Lung Neoplasms
Fluorescent Antibody Technique
Diagnostic accuracy
chemokines
Immunofluorescence
Sensitivity and Specificity
CXCR4
Carcinoma, Non-Small-Cell Lung
Biomarkers, Tumor
Genetics
medicine
Humans
metastasis
Lung cancer
Neoplasm Staging
marker
medicine.diagnostic_test
Receiver operating characteristic
Brain Neoplasms
business.industry
digestive, oral, and skin physiology
Brain metastases
General Medicine
Middle Aged
CXCL12
medicine.disease
Chemokine CXCL12
respiratory tract diseases
stomatognathic diseases
lung cancer
ROC Curve
Oncology
Area Under Curve
immunohistochemistry
Female
Non small cell
prognosis
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Disease markers. Section A, Cancer biomarkers, info:cnr-pdr/source/autori:Paratore, Sabrina; Banna, Giuseppe Luigi; D'Arrigo, Maria; Saita, Salvatore; Iemmolo, Rosario; Lucenti, Letizia; Bellia, Domenico; Lipari, Helga; Buscarino, Calogero; Cunsolo, Rosario; Cavallaro, Sebastiano/titolo:CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases/doi:10.3233%2FCBM-2011-0232/rivista:Disease markers. Section A, Cancer biomarkers (Print)/anno:2011/pagina_da:79/pagina_a:89/intervallo_pagine:79–89/volume:10
- Accession number :
- edsair.doi.dedup.....9a42ff0c93fc73b92f264a0434005fec